Caricamento...

Aberrant expression of ERG promotes resistance to combined PI3K and AR pathway inhibition through maintenance of AR target genes

Based on our previous work defining the molecular rationale for combined targeting of the PI3K and AR pathways in PTEN loss prostate cancer, the first clinical trial was recently reported demonstrating a significant benefit for combination therapy in patients with metastatic prostate cancer. In this...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cancer Ther
Autori principali: Mao, Ninghui, Gao, Dong, Hu, Wenhuo, Hieronymus, Haley, Wang, Shangqian, Lee, Young Sun, Lee, Cindy, Choi, Danielle, Gopalan, Anuradha, Chen, Yu, Carver, Brett S
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726496/
https://ncbi.nlm.nih.gov/pubmed/31296553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-1386
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !